Watertown, Massachusetts-based Disc has agreed with the FDA that it will use average monthly time in sunlight during the last ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up ...

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to ...

Join the ultimate European gathering of microbiome innovators dedicated to translating groundbreaking research into viable, ...

Building on 7 years of success, the 8th Antigen-Specific Immune Tolerance Summit is back - the only conference dedicated to ...

Join us at the 2nd Protein Degradation for CNS Summit - an unparalleled event dedicated to delivering protein degraders to ...